A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways, particularly those ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery.

Conductor Daniel Barenboim says he has been diagnosed with Parkinson's disease. The 82-year-old issued a statement Thursday ...

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...